Impact of the comprehensive geriatric assessment on treatment decision in geriatric oncology.

CURRENT STATUS: ACCEPTED

Sandrine Sourdet
Centre Hospitalier Universitaire de Toulouse
sourdet.s@chu-toulouse.fr
ORCiD: https://orcid.org/0000-0001-8967-8915

Delphine Brechemier
Centre Hospitalier Universitaire de Toulouse

Zara Steinmeyer
Centre Hospitalier Universitaire de Toulouse

Stephane Gerard
Centre Hospitalier Universitaire de Toulouse

Laurent Balardy
Centre Hospitalier Universitaire de Toulouse

DOI: 10.21203/rs.2.12137/v3

SUBJECT AREAS
- Oncology
- Cancer Biology

KEYWORDS
- Geriatric oncology; Geriatric assessment; Treatment decision-making; Physical performance; Cognitive impairment; Malnutrition
Abstract
Background: The comprehensive geriatric assessment (CGA) is the gold standard in geriatric oncology to identify patients at high risk of adverse outcomes and optimize cancer and overall management. Many studies have demonstrated that CGA could modify oncologic treatment decision. However, there is little knowledge on which domains of the CGA are associated with this change. Moreover, the impact of frailty and physical performance on change in cancer treatment plan has been rarely assessed.

Methods: This is a cross-sectional study of older patients with solid or hematologic cancer referred by oncologists for a geriatric evaluation before cancer treatment. A comprehensive geriatric assessment was performed by a multidisciplinary team to provide guidance for treatment decision. We performed a multivariate analysis to identify CGA domains associated with change in cancer treatment plan.

Results: 418 patients, mean age 82.8 ± 5.5, were included between October 2011 and January 2016, and 384 of them were referred with an initial cancer treatment plan. This initial cancer treatment plan was changed in 64 patients (16.7%). In multivariate analysis, CGA domains associated with change in cancer treatment plan were cognitive impairment according to the MMSE score (p=0.020), malnutrition according to the MNA score (p=0.023), and low physical performance according to the Short Physical Performance Battery (p=0.010).

Conclusion: Cognition, malnutrition and low physical performance are significantly associated with change in cancer treatment plan in older adults with cancer. More studies are needed to evaluate their association with survival, treatment toxicity and quality of life. The role of physical performance should be specifically explored.

Background
There is rising incidence and prevalence of cancer in older adults worldwide. In 2017, France, 65% of all cancers were diagnosed in older adults aged 65 years and above (1). By 2030, 70% of all cancers will occur in patients aged over 65 years in the USA (2). Because of the complexity of this population, the management of older adults with cancer is challenging. Oncologic treatment is often based on chronological age (3), but it does not reflect the heterogeneity of this population and predicts poorly
treatment tolerance. There is growing evidence that the decision-making process should be rather based on patient’s functional age (4).

The comprehensive geriatric assessment (CGA) is an effective tool for assessing a patient’s functional age. It has been proven to be a strong predictor of adverse events in geriatric oncology patients, and is recommended in treatment decision making by the International Society of Geriatric Oncology (SIOG)(5). According to the SIOG, the following domains of the CGA need to be evaluated: functional status, comorbidity, medication, cognition, fatigue, psychosocial status, nutrition and geriatric syndromes assessment (5). In addition to this usual assessment, frailty assessment is increasingly recommended in the oncogeriatric approach and reflects well functional reserve (6). Frailty is a state of vulnerability to poor resolution of homeostasis following stress. In the oncogeriatric population, frailty is associated with poor outcomes such as surgical complications, chemotherapy and radiotherapy morbidity and mortality (6,7). Many tools have been developed to identify frailty: the most common being the Fried’s criteria (8), and the frailty Index (9), but physical performance tests such as gait speed, or the short physical performance Battery (SPPB) may perform as well (10). Poor SPPB score, gait speed, or Timed Up & Go (TUG) Test are associated with mortality, treatment complications, and functional decline (11–13). Nevertheless they have been insufficiently studied in the treatment decision process in geriatric oncology.

The CGA has been recommended in oncology practice for many reasons: identification of health problems usually not screened during routine oncological assessment, implementing non-oncologic interventions, but also change in cancer treatment plan. In a recent review, Hamaker et al. showed that the CGA modified the oncologic treatment plan in 8 to 54% of patients (14). But there is little knowledge on which CGA domain could influence changes in cancer treatment decision. Only a few studies have tried to identify CGA parameters associated with change in cancer treatment plan (14). Frailty and physical performance are rarely assessed.

In this study, we aimed to identify domains of CGA associated with change in cancer treatment plan in older patients with cancer, including frailty and physical performance.

Methods
In Toulouse University Hospital, a geriatric consultation team including a geriatrician experienced in oncology (with an university degree in geriatric oncology) and a geriatric nurse, can be requested by an oncologist, surgeon or radiation therapist, to provide a geriatric expertise in older patients with cancer in various hospital units (15). They perform a one-hour geriatric assessment at the patient’s bedside and give conclusions about geriatric impairment, subsequent interventions, and if needed they can provide guidance for cancer treatment decision. In complex clinical situations or treatment plans, a more complete geriatric evaluation may be advised so the oncogeriatric patients are referred to the Geriatric Frailty Clinic.

The geriatric frailty clinic (GFC) is a geriatric day hospital of the Gerontopole of Toulouse, France, dedicated to the prevention of disability in frail older patients. It also evaluates patients aged 65 years and older with solid or hematological cancer during a pre-therapeutic evaluation. Its organization and overall activity are well described elsewhere (16). Each patient undergoes a CGA performed by a multidisciplinary geriatric team (including a geriatrist or a general practitioner specifically trained in geriatrics, a nurse, a nurse-aid, an orthoptist (paramedical profession specialized in the eye care sector), and if needed a dietician, a neuropsychologist, and a physical activity teacher). In geriatric oncology patients, a geriatrician specialized in oncology is also consulted.

The first objective of the evaluation is to provide guidance concerning cancer treatment decision. The CGA is a recommended assessment able to: 1/ give helpful information concerning the existence of unidentified health-related problems and geriatric syndromes, 2/ help to estimate life-expectancy in the context of cancer, comorbidities and geriatric status, 3/ predict treatment-related complications and overall survival (5). At the end of the evaluation, during a multi-professional meeting, the geriatric team and the geriatrician specialized in oncology, propose to maintain or change the initial cancer treatment plan, according to the conclusions of the CGA. Changes in cancer treatment may be graded as follow: intensification of cancer treatment, decrease in treatment intensity or change from specific cancer treatment to supportive care. In case of change, the geriatric proposal is discussed with the referring practitioner, who will decide the final treatment. The decision-making process is
described in Figure 1. A second objective of the CGA is to propose therapeutic and non-therapeutic interventions to optimize the patient’s health status before the cancer treatment.

In this analysis, oncogeriatric patients evaluated between October 2011 and January 2016 were included. Ethics approval for this study was obtained from the local ethic committee in Toulouse University Hospital.

**Comprehensive geriatric assessment**

A CGA was performed for all consecutive patients. Social environment assessment included living conditions and marital status. A medical evaluation recorded the type and stage of cancer.

Comorbidities were assessed according to the Charlson Comorbidity Index (17). Polypharmacy was defined as five or more prescribed medications (18). Functional abilities were assessed using Kat’z Activities of Daily Living (ADL) and Lawton’s Instrumental Activities of Daily Living (19,20). Frailty and physical function were measured respectively using Fried’s Criteria (8) and the Short Physical Performance Battery (SPPB) (21). Frailty criteria included 1) unintended weight loss, 2) self-reported exhaustion, 3) low hand-grip strength (as measured by a dynamometer and stratified by BMI and sex), 4) slow walking speed (4 meters usual walk speed stratified by height and sex) and 5) low physical activity. Patients were classified as frail if they met at least three criteria, pre-frail if they met one or two criteria, and robust if they met no criteria. The SPPB consists of three measurements: 1) standing balance test, 2) four meters walking speed and, 3) chair stand. Patients were categorized into three groups according to the SPPB score: high performance (score 10-12), medium performance (score 6-9), low performance (score 0-6). The G-8 geriatric screening tool, which is usually used to determine what patients would benefit from CGA, was also assessed (22). A cut-off less or equal to fourteen is usually admitted to identify vulnerable patients who need a CGA (22).

Cognition was evaluated using the Mini Mental State Evaluation (MMSE) (23). A MMSE score of 24 or less was used to identify cognitive impairment (24). The nutritional status was assessed by the Mini Nutritional Assessment (MNA) (25). A MNA score ≥ 24 indicates a good nutritional status, a score of 17-23.5 indicates a risk of malnutrition and a score less than seventeen indicates malnutrition. The Hearing Handicap Inventory for the Elderly-Screening (HHIE-S), a self-assessment scale, was used to
assess hearing loss (26). An ophthalmologic evaluation was performed focusing on near vision (Parinaud chart), distance vision (Snellen chart) and detection of age-related macular degeneration (using Amsler grid). Visual impairment is defined using definitions detailed in a former work (27).

**Statistical analysis**

We performed a descriptive analysis of the patients, cancers, and treatments characteristics. We performed a bivariate analysis to compare the CGA characteristics of the patients according to the change in cancer treatment plan (change or no change). Chi-square test or Fisher exact test were used for qualitative variables, and Student’s t test (in case of normal distribution) or the Mann-Whitney non-parametric test were used for quantitative variables. A multivariate logistic regression, using backward selection, was performed to test the association between CGA components and change in treatment decision. The multivariate model was built using variables which were associated in the bivariate analysis with a p-value<0.20. Collinear variables were not entered in the final model. Interactions were tested according to clinical judgment. Statistical analyses were carried out using STATA version 11 (STATA Corp., TX USA).

**Results**

A total of 452 patients, aged 65 or older, were referred to the GFC between October 2011 and January 2016 by their oncologist, hematologist, surgeon or radiation therapist. Thirty four patients were excluded from the analysis: six because their diagnosis of cancer was uncertain or still under investigation; seventeen due to poor health status of the patient where a complete clinical assessment was not feasible; and eleven had a diagnosis of hematologic disease without specific treatment plan (10 myelodysplastic syndrome and 1 monoclonal gammopathy), and were not evaluated specifically in the context of their hematologic diseases but for geriatric issues. Patients referred by their hematologist with myelodysplastic syndrome (MDS) and a systemic anti-MDS treatment plan were kept in the analysis. Descriptive statistics and demographic variables of the 418 remaining patients with cancer are described in table 1 and 2.

The most prevalent cancers in men were digestive cancers (34.1%) especially colorectal cancers (64.9% of digestive cancers). In women the most frequent cancers were gynecologic cancers (34.3%)
and mainly breast cancer (75.4% of gynecologic cancers).

Most of the patients were assessed before surgery or chemotherapy (77.8%) (Table 3). Targeted therapies were proposed only to 7 patients (1.7%). Thirty-four patients were admitted only for supportive care treatment, with no cancer treatment plan defined (cancer treatment was already achieved for 17 patients, and not decided for the others).

Among the 384 patients evaluated with an initial cancer treatment plan, the treatment was changed in 16.7% (n=64) of patients. There was no proposal to increase the intensity of the initial cancer treatment plan in this sample. A decrease of the intensity of the chemotherapy (dose adaptation of the chemotherapy or proposition of a single agent therapy instead of a combination therapy) was suggested in 8 patients (2.1%). Supportive care was recommended in 32 patients (57.1%), and a less aggressive treatment was suggested for the others (mainly radiotherapy instead of surgery or “surgery and chemotherapy” in 13 patients (23.2%), and hormonal therapy instead of chemotherapy or surgery in 5 patients (8.9)).

After discussion with the referring practitioner, his initial cancer treatment plan was maintained in 6 patients (9.7%), and the change in cancer treatment was carried out by the oncologist in 56 patients (90.3%). One patient was lost to follow-up.

As for the 63 patients with a normal G-8 score (16% of the population included), the treatment was changed only for three patients (4.8% of the patients with a normal G-8 score).

In the bivariate analysis, age, cognitive function, nutrition, activities of daily living, instrumental activities of daily living, physical performance (SPPB), gait speed, Fried criteria and visual impairment were significantly associated with change in the initial cancer treatment plan. In the multivariate analysis, a MMSE score less than 24, a malnutrition assessed with a MNA score less than seventeen, and low physical performance (SPPB£7) were significantly associated with change in the initial cancer treatment plan (Table 4). An interaction between physical performance (assessed by SPPB) and nutrition (assessed with MNA) was tested but was not significant (data not shown).

Discussion

The decision-making process in older patients with cancer is challenging. In our study population, the
initial cancer treatment plan was deemed inappropriate for 16.7% of patients (n=64). A low MMSE score, malnutrition, and low physical performance were independently associated with change in the initial cancer treatment plan. In previous studies exploring the impact of geriatric evaluations on treatment decisions in older patients with cancer, the oncologic treatment was modified in 8 to 54% of all patients (with a median of 28%) (14). In our study, the initial cancer treatment plan was changed in only 16.7% of patients. This difference may be difficult to compare with previous studies because of the populations heterogeneity, the various types of cancer, the various geriatric evaluations and different settings (14). Nevertheless, oncogeriatric evaluation has been implemented in routine clinical practice for a few years in our clinical setting (15), and may have influenced and improved decision-making in this discipline. In addition, geriatric treatment recommendations were closely followed-up by the oncologist when the initial treatment plan was changed (in 91.1% of patients).

In cancer treatment, malnutrition is a substantial parameter to consider, because of its association with treatment toxicity and mortality (28). In our study, malnutrition is significantly associated with changes in planned cancer treatment. Our results are consistent with past studies exploring CGA parameters associated with change in cancer treatment decision. In two studies, a low BMI under 21 kg/m2 was associated with a modification of the cancer treatment plan (29,30), and according to Cailet et al. malnutrition evaluated by MNA, BMI, weight loss or low serum albumin was also associated with changes in cancer treatment (mainly a decrease in treatment intensity) (31). In our analysis, malnutrition was defined only with the MNA score, which may have underestimated the prevalence of malnutrition in this population.

Another CGA parameter significantly linked with change in cancer treatment plan is a MMSE score under 24. Many factors can explain the fact that cognitive impairment may trigger a change in cancer treatment, preferentially from an aggressive treatment to a less aggressive option. First, past studies suggest that older patients with cognitive impairment are less compliant with treatment, which could affect the benefit of chemotherapy for example (32). Secondly, discussion and understanding regarding treatment options may be more complex in this population: this may jeopardize the choice
of the treatment. When decision-making capacity is deteriorated, patients tend to choose preferentially the less aggressive option (33). Third there is evidence that chemotherapy can worsen cognitive functions (34). Furthermore cognitive impairment is associated with cancer mortality or the probability of not completing chemotherapy (35–37). But the impact of cognitive impairment or dementia on chemotherapy tolerance, hospitalizations or patient-reported outcome measures remains insufficiently investigated and unclear (38). To our knowledge, only one study concluded that a low MMSE score (<26) was associated with change in cancer treatment plan, specifically in lung cancer (39). The impact of pre-existing cognitive-impairment on cancer-related outcomes needs to be clarified to improve cancer decisions and care in older adults.

In this study, low physical performance defined by a SPPB score less or equal to six, is associated with change in the initial cancer treatment plan. Physical performance tests reflect well frailty in oncogeriatric patients and are easy and rapid to use in clinical settings (11). In previous studies exploring the effect of CGA on treatment decisions, physical performance were not systematically tested or were sometimes limited to the number of falls (29,30,40). According to Farcet et al., the number of Fried’s criteria was significantly associated with a modification of the initial cancer treatment plan (41). In our study, frailty according to the same definition, was not significantly associated with change in treatment plan. As most of the patients were frail or prefrail (only 8% were robust), this information is probably not relevant to clinicians. They prefer to base their judgment mainly on the results of the SPPB which seems to offer a better discrimination of subjects with poor physical performance. This is the first time that the SPPB score is identified as a test that could be useful to modify treatment decision in oncogeriatric patients. Its use in routine clinical practice should be considered when evaluating oncogeriatric patients.

This study has some limitations. First, some parameters usually assessed in a geriatric evaluation (such as mood, BMI, or weight loss), were not systematically recorded in our dataset and were not exploited in this analysis. Then, the geriatric assessment was operated in only one hospital, by the same medical team, which may prevent reproducible research in other clinical settings. Moreover, oncologists referred patients to the frailty clinic without using an identified screening tool, but mainly
according to their clinical judgment (if the patient seems frail or not). The results of the G-8 assessment show that they referred mainly patients (84%) that needed a CGA. But on the other hand, they may have selected only the frailest patients, and overestimate the robustness of the other patients, who would have been identified as vulnerable with an assessment tool. Indeed, past studies have shown that oncologist’s ability to identify frailty only according to their clinical judgment was low compared to CGA (42,43). This is a potential bias in this study. Finally, a wide spectrum of cancer was included in this work, at different stages, with a wide range of treatments, and with different level of possible complications. It is possible that the decision-making process is different according to the type and stage of cancer, and the type of treatment planned. Specific studies should be planned in the most prevalent cancers and according to the type of treatment to establish specific guidelines in older patient with cancer. This study has also several strengths: this is one of the few studies to evaluate the role of physical performance (SPPB or gait speed) in treatment decision in oncogeriatric patients. We used only international validated tools to assess domains of the CGA, as part of a multidisciplinary evaluation (5), and the median age was relatively high (83 years) (in a previous review evaluating the effect of geriatric evaluation on treatment decisions and outcomes, the median age ranged from 74 to 83 years) (14).

Conclusions
In conclusion, this study shows that nutrition, physical performance and cognition are geriatric factors significantly associated with change in cancer treatment decisions in oncogeriatric patients. Prospective studies are needed to confirm their impact on treatment tolerance, cancer mortality, disability and patient-related outcomes, especially in highly-prevalent cancers.

List Of Abbreviations
ADL: Activities of Daily Living; BMI: Body Mass Index; CGA: Comprehensive Geriatric Assessment; GFC: Geriatric Frailty Clinic; HHIE-S: Hearing Handicap Inventory for the Elderly-Screening; MMSE: Mini-Mental State Examination; MNA: Mini-Nutritional Assessment; SIOG: International Society of Geriatric Oncology; SPPB: Short Physical Performance Battery; TUG: Timed Up and Go Test

Declarations

Ethics approval and consent to participate:
The ethics approval was delivered by the local ethic committee in Toulouse University Hospital.

Considering the data used in this article are those from usual care no specific consent was judged necessary according to the French regulation.

**Consent for publication:**

Not applicable

**Availability of data and materials:**

The dataset used and analyse during the current study are available from the corresponding author on reasonable request.

**Competing interests:**

The authors declare they have no competing interests.

**Funding:**

Not applicable

**Author contribution**

SS, DB, SG, and LB conceived and designed the study.

SS performed the data acquisition, quality control and statistical analysis.

SS, ZS, and LB interpreted the data.

SS wrote the first draft of the paper and prepared figures and tables.

All authors revised the manuscript and approved the final version.

**Acknowledgments**

We would like to thank the “Geriatric Frailty Clinic” team for their valuable work: H Gesta, MP Bautrait, S Merabet, C Dupuy, G Soriano, MC Picauron, E Combrouze, T Gemar, A Ghisolfi, S Oberdorff, C Oliveira.

**References**

1. Jéhannin-Ligier K, Dantony E, Bossard N, Molinié F, Defossez G, Daubisse-Marliac L, et al. Projection de l’incidence et de la mortalité par cancer en France métropolitaine en 2017. Rapport technique. Saint-Maurice: Santé publique France; 2017.

2. White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer
risk: a potentially modifiable relationship. Am J Prev Med. 2014 Mar;46(3 Suppl 1):S7–15.

3. Mcmillan. The age old excuse: the under treatment of older cancer patients. [Internet]. 2012. Available from:
   www.macmillan.org.uk/Documents/GetInvolved/Campaigns/AgeOldExcuse/

4. Soto-Perez-de-Celis E, Li D, Yuan Y, Lau YM, Hurria A. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol. 2018;19(6):e305–16.

5. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014 Aug 20;32(24):2595–603.

6. Huisingh-Scheetz M, Walston J. How should older adults with cancer be evaluated for frailty? J Geriatr Oncol. 2017;8(1):8–15.

7. Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol Off J Eur Soc Med Oncol. 2015 Jun;26(6):1091–101.

8. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146–56.

9. Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2001 Aug 8;1:323–36.

10. Abellan van Kan G, Rolland Y, Bergman H, Morley JE, Kritchevsky SB, Vellas B. The I.A.N.A Task Force on frailty assessment of older people in clinical practice. J Nutr Health Aging. 2008 Jan;12(1):29–37.
11. Verweij NM, Schiphorst AHW, Pronk A, van den Bos F, Hamaker ME. Physical performance measures for predicting outcome in cancer patients: a systematic review. Acta Oncol Stockh Swed. 2016 Dec;55(12):1386–91.

12. Pamoukdjian F, Paillaud E, Zelek L, Laurent M, Lévy V, Landre T, et al. Measurement of gait speed in older adults to identify complications associated with frailty: A systematic review. J Geriatr Oncol. 2015 Nov;6(6):484–96.

13. Pamoukdjian F, Lévy V, Sebbane G, Boubaya M, Landre T, Bloch-Queyrat C, et al. Slow Gait Speed Is an Independent Predictor of Early Death in Older Cancer Outpatients: Results from a Prospective Cohort Study. J Nutr Health Aging. 2017;21(2):202–6.

14. Hamaker ME, Te Molder M, Thielen N, van Munster BC, Schiphorst AH, van Huis LH. The effect of a geriatric evaluation on treatment decisions and outcome for older cancer patients - A systematic review. J Geriatr Oncol. 2018 Sep;9(5):430–40.

15. Rougé-Bugat ME, Gérard S, Balardy L, Beyne-Rauzy O, Boussier N, Perrin A, et al. Impact of an oncogeriatric consulting team on therapeutic decision-making. J Nutr Health Aging. 2013;17(5):473–8.

16. Tavassoli N, Guyonnet S, Abellan Van Kan G, Sourdet S, Krams T, Soto ME, et al. Description of 1,108 older patients referred by their physician to the “Geriatric Frailty Clinic (G.F.C) for Assessment of Frailty and Prevention of Disability” at the gerontopole. J Nutr Health Aging. 2014 May;18(5):457–64.

17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

18. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 10;17(1):230.
19. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. JAMA. 1963 Sep 21;185:914–9.

20. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. The Gerontologist. 1969;9(3):179–86.

21. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994 Mar;49(2):M85–94.

22. Bellera CA, Rainfray M, Mathoulin-Pélissier S, Mertens C, Delva F, Fonck M, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol Off J Eur Soc Med Oncol. 2012 Aug;23(8):2166–72.

23. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189–98.

24. Lezak M, Howieson D, Loring D. Neuropsychological assessment. Oxford University Press. 2004. (4th edition).

25. Guigoz Y, Vellas B. The Mini Nutritional Assessment (MNA) for grading the nutritional state of elderly patients: presentation of the MNA, history and validation. Nestle Nutr Workshop Ser Clin Perform Programme. 1999;1:3-11; discussion 11–2.

26. Ventry IM, Weinstein BE. The hearing handicap inventory for the elderly: a new tool. Ear Hear. 1982 Jun;3(3):128-34.

27. Soler V, Sourdet S, Balardy L, Abellan van Kan G, Brechemier D, Rougé-Bugat ME, et al. Visual Impairment Screening at the Geriatric Frailty Clinic for Assessment of Frailty and Prevention of Disability at the Gérontopôle. J Nutr Health Aging.
28. Caillet P, Liuu E, Raynaud Simon A, Bonnefoy M, Guerin O, Berrut G, et al. Association between cachexia, chemotherapy and outcomes in older cancer patients: A systematic review. Clin Nutr Edinb Scotl. 2017;36(6):1473–82.

29. Girre V, Falcou M-C, Gisselbrecht M, Gridel G, Mosseri V, Bouleuc C, et al. Does a geriatric oncology consultation modify the cancer treatment plan for elderly patients? J Gerontol A Biol Sci Med Sci. 2008 Jul;63(7):724–30.

30. Marenco D, Marinello R, Berruti A, Gaspari F, Stasi MF, Rosato R, et al. Multidimensional geriatric assessment in treatment decision in elderly cancer patients: 6-year experience in an outpatient geriatric oncology service. Crit Rev Oncol Hematol. 2008 Nov;68(2):157–64.

31. Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol Off J Am Soc Clin Oncol. 2011 Sep 20;29(27):3636–42.

32. El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication Adherence in Older Patients With Dementia: A Systematic Literature Review. J Pharm Pract. 2018 Jun;31(3):322–34.

33. Clarke G, Fistein E, Holland A, Barclay M, Theimann P, Barclay S. Preferences for care towards the end of life when decision-making capacity may be impaired: A large scale cross-sectional survey of public attitudes in Great Britain and the United States. PloS One. 2017;12(4):e0172104.

34. Moore HCF. An overview of chemotherapy-related cognitive dysfunction, or “chemobrain.” Oncol Williston Park N. 2014 Sep;28(9):797–804.

35. Katsoulis M, Kyrozis A, Trichopoulou A, Bamia C, Trichopoulos D, Lagiou P. Cognitive impairment and cancer mortality: a biological or health care explanation? Cancer
36. Raji MA, Kuo Y-F, Freeman JL, Goodwin JS. Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care. Arch Intern Med. 2008 Oct 13;168(18):2033-40.

37. Aaldriks AA, Maartense E, le Cessie S, Giltay EJ, Verlaan H a. CM, van der Geest LGM, et al. Predictive value of geriatric assessment for patients older than 70 years, treated with chemotherapy. Crit Rev Oncol Hematol. 2011 Aug;79(2):205-12.

38. Karuturi M, Wong ML, Hsu T, Kimmick GG, Lichtman SM, Holmes HM, et al. Understanding cognition in older patients with cancer. J Geriatr Oncol. 2016;7(4):258-69.

39. Aliamus V, Adam C, Druet-Cabanac M, Dantoine T, Vergnenegre A. [Geriatric assessment contribution to treatment decision-making in thoracic oncology]. Rev Mal Respir. 2011 Nov;28(9):1124-30.

40.Chaïbi P, Magné N, Breton S, Chebib A, Watson S, Duron J-J, et al. Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. Crit Rev Oncol Hematol. 2011 Sep;79(3):302-7.

41. Farcet A, de Decker L, Pauly V, Rousseau F, Bergman H, Molines C, et al. Frailty Markers and Treatment Decisions in Patients Seen in Oncogeriatric Clinics: Results from the ASRO Pilot Study. PloS One. 2016;11(2):e0149732.

42. Kirkhus L, Šaltytė Benth J, Rostoft S, Grønberg BH, Hjermstad MJ, Selbæk G, et al. Geriatric assessment is superior to oncologists’ clinical judgement in identifying frailty. Br J Cancer. 2017 Aug 8;117(4):470-7.

43. Wedding U, Ködding D, Pientka L, Steinmetz HT, Schmitz S. Physicians’ judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol. 2007 Oct;64(1):1-9.
### Tables

Table 1: Descriptive analysis of the 418 oncogeriatric patients evaluated at the Geriatric Frailty Clinic: socio-demographic characteristics and CGA domains.

| Characteristics                        | Mean ± SD or N (%) |
|----------------------------------------|--------------------|
| **Socio-demographic characteristics**  |                    |
| Age (years)                            | 82.8 ± 5.5         |
| Gender (female)                        | 201 (48.1)         |
| Living conditions (n=412)              |                    |
| Live alone                             | 147 (35.7)         |
| Marital status                         |                    |
| Married (vs widowed, single or divorced)| 203 (48.6)         |
| Education (n=415)                      |                    |
| No education or Elementary School      | 232 (55.9)         |
| Middle/ High School/ College           | 183 (44.1)         |
| **Medical characteristics**            |                    |
| Charlson Comorbidity Index             | 1.4 ± 1.6          |
| Number of drugs                        |                    |
| Drugs ≥ 5                              | 5.7 ± 3.2          |
| G-8 score ≤14 (n=397)                  | 334 (84.1)         |
| **Cognitive assessment**               |                    |
| MMSE £ 24 (n=405)                      | 149 (36.8)         |
| **Nutritional assessment**             |                    |
| MNA (n=411)                            |                    |
| MNA ≥ 24                               | 169 (41.1)         |
| MNA (17-23.5)                          | 201 (48.9)         |
| MNA<17                                 | 41 (10.0)          |
| **Physical assessment**                |                    |
| ADL £ 5                                | 118 (28.2)         |
| IADL £ 7                               | 326 (78.0)         |
| SPPB (n=414)                           |                    |
| 10-12 (high performance)               | 126 (30.4)         |
| 7-9 (medium performance)               | 139 (33.6)         |
| £ 6 (low performance)                  | 149 (36.0)         |
| Gait speed (<1m/s)                     | 324 (77.5)         |
| Grip strength (kg)                     |                    |
| Women                                  | 16.1 ± 5.4         |
| Men                                    | 26.6 ± 7.5         |
| **Fried’s criteria**                   |                    |
| Robust (0 criteria)                    | 33 (7.9)           |
| Pre-frail (1-2 criteria)               | 155 (37.1)         |
| Frail (≥ 3 criteria)                   | 230 (55.0)         |
| **Sensory assessment**                 |                    |
| HHIES score (n=389)                    |                    |
| No hearing handicap                    | 224 (57.6)         |
| Mild-moderate hearing handicap         | 143 (36.8)         |
| Significant hearing handicap           | 22 (5.7)           |
| Visual deficit                         | 211 (57.3)         |

SD=Standard Derivation, G-8=Geriatric-8 Score, MMSE=Mini Mental State Examination, MNA=Mini-Nutritional Assessment, ADL=Activities of Daily Living, IADL=Instrumental Activities of Daily Living,
SPPB= Short Physical Performance Battery, HHIES=Hearing Handicap Inventory for the Elderly - Screening.

Table 2: Type and stage of cancer in the 418 oncogeriatric patients evaluated at the Geriatric Frailty Clinic

| Characteristics                      | N (%)          |
|--------------------------------------|----------------|
| **Type of cancers (solid cancers)**  | 339 (81.1)     |
| Digestive cancer                     | 124 (29.7)     |
| Colorectal                           | 86 (69.3)      |
| Stomach                              | 10 (8.1)       |
| Pancreas cancer                      | 11 (8.9)       |
| Other (esophageal, hepatic, duodenal, cholangiocarcinoma ...) | 17 (13.7) |
| Urologic cancer                      | 77 (18.4)      |
| Bladder                              | 41 (53.2)      |
| Kidney                               | 26 (33.8)      |
| Prostate                             | 10 (13.0)      |
| Gynecologic cancer                   | 70 (16.8)      |
| Breast                               | 52 (74.3)      |
| Ovarian                              | 9 (12.9)       |
| Other                                | 9 (12.9)       |
| Head and neck Cancer                 | 24 (5.7)       |
| Lung cancer                          | 18 (4.3)       |
| Skin cancer                          | 10 (2.4)       |
| Melanoma                             | 3 (0.30%)      |
| Non-melanoma                         | 7 (0.70%)      |
| Other                                | 16 (3.8)       |
| **Cancer stage**                     |                |
| Local                                | 155 (37.1)     |
| Loco-regional                        | 75 (17.9)      |
| Metastasis                           | 109 (26.1)     |
| Hematological cancer                 | 79 (18)        |
| Lymphoma                             | 23 (29.1)      |
| Acute myelogenous leukemia, Myelodysplastic syndrome | 1 (1.3) |
|                                     | 8 (10.1)       |
| Multiple myeloma                      | 13 (16.5)      |
| Chronic lymphocytic leukemia          | 34 (43.0)      |

Table 3: Reason for assessment and decision after the comprehensive geriatric assessment:
| Initial Cancer treatment plan | N (%) |
|------------------------------|-------|
| Surgery                      | 173 (41.4) |
| Chemotherapy                 | 148 (35.4) |
| Adjuvant chemotherapy        | 18 (4.3) |
| Radiotherapy                 | 11 (2.6) |
| Chemotherapy and surgery     | 4 (1.0) |
| Chemotherapy and radiotherapy| 6 (1.5) |
| Surgery and radiotherapy     | 2 (0.5) |
| Hormonal therapy             | 13 (3.1) |
| Hormonal therapy and radiotherapy | 1 (0.2) |
| Targeted therapy             | 6 (1.5) |
| Hormonal therapy and targeted therapy | 1 (0.2) |
| Chemoembolization            | 1 (0.2) |
| Supportive care treatment    | 34 (8.1) |

| Change in the initial cancer treatment plan  (except for patients admitted for “supportive care treatment”) | N (%) |
|-------------------------------------------------------------------------------------------------|-------|
| No change                                                                                       | 320 (83.3) |
| Change (decrease in chemotherapy intensity)                                                    | 8 (2.1) |
| Change from specific cancer treatment to supportive care or less aggressive treatment           | 56 (14.6) |

Table 4: Bivariate and multivariate association between change in the initial cancer treatment plan and comprehensive geriatric assessment:
| Characteristics                                      | Bivariate OR (95% CI) | p    | Multivariate OR (95% CI) |
|------------------------------------------------------|-----------------------|------|--------------------------|
| Age (years)                                          | 1.06 (1.01-1.11)      | 0.014| -                        |
| Gender (female)                                      | 1.27 (0.74-2.17)      | 0.386| -                        |
| Living conditions (Live alone)                       | 1.07 (0.60-1.90)      | 0.827| -                        |
| Marital status                                       |                       |      |                          |
| Married (vs widowed, single or divorced)             | 0.85 (0.49-1.46)      | 0.553| -                        |
| Education (n=438)                                    |                       |      |                          |
| Middle/ High School/ College (vs no education or elementary school) | 0.71 (0.41-1.24)      | 0.235| -                        |
| Charlson Comorbidity Index                           | 1.06 (0.99-1.26)      | 0.466| -                        |
| Number of drug (≥ 5)                                 | 1.77 (0.98-3.19)      | 0.057| -                        |
| MMSE (£24)                                           | 3.53 (1.98-6.29)      | <0.001| 2.15 (1.13-4.12)         |
| MNA (n=429)                                          |                       |      |                          |
| MNA ≥ 24                                             | 1                     |      | 1                        |
| MNA (17-23.5)                                        | 2.45 (1.22-4.93)      | 0.012| 1.44 (0.62-3.34)         |
| MNA<17                                               | 11.08 (4.68-26.22)    | <0.001| 3.33 (1.18-9.37)         |
| ADL (£5)                                             | 4.64 (2.65-8.12)      | <0.001| -                        |
| IADL (£7)                                            | 7.12 ((2.17-23.30)    | 0.001| -                        |
| SPPB                                                 |                       |      |                          |
| 10-12 (high performance)                             |                       |      | 1                       |
| 7-9 (medium performance)                             | 1.91 (0.69-5.27)      | 0.210| 1.50 (0.45-4.98)         |
| £ 6 (low performance)                                | 9.56 (3.90-23.40)     | <0.001| 4.55 (1.43-14.46)        |
| Gait speed (<1m/s)                                   | 3.22 (1.34-7.75)      | 0.009| -                        |
| Fried's criteria                                     |                       |      |                          |
| Robust (0 criteria)                                  | 1                     |      | 1                       |
| Pre-frail (1-2 criteria)                             | 0.39 (0.09-1.65)      | 0.200| -                        |
| Frail (≥ 3 criteria)                                 | 3.21 (0.94-11.01)     | 0.063| -                        |
| Hearing impairment                                   | 0.89 (0.49-1.60)      | 0.694| -                        |
| Visual impairment                                    | 2.01 (1.06-3.83)      | 0.031| -                        |

OR=Odds Ratio, MMSE=Mini Mental State Examination, MNA=Mini-Nutritional Assessment, ADL=Activities of Daily Living, IADL=Instrumental Activities of Daily Living, SPPB= Short Physical Performance Battery, HHIES=Hearing Handicap Inventory fort the Elderly – Screening.

Figures
Decision making-process for the older patients with cancer referred to the geriatric frailty
clinic.